Completed PHASE4 INTERVENTIONAL 1-arm NCT04529005

Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients

Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant

Sponsor: La Jolla Pharmaceutical Company

Conditions Hypotension and Shock Intraoperative Hypotension Kidney Transplant; Complications Postoperative Hypotension Shock Shock, Surgical

Interventions Angiotensin II

Updated 6 times since 2020 Last updated: Nov 26, 2022 Started: Aug 13, 2020 Primary completion: Aug 1, 2021 Completion: Aug 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Hypotension and Shock and Intraoperative Hypotension, this trial is completed. The trial is conducted by La Jolla Pharmaceutical Company and has accumulated 6 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Sep 2021 — Jan 2023 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE4

▶ Show 1 earlier version

Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE4

First recorded

Aug 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

La Jolla Pharmaceutical Company
University of Illinois at Chicago

Data source: University of Illinois at Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States